Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,742 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergic Reactions Clear all
Active, not recruiting Phase 3 Interventional

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
16
States / cities
Paradise Valley, Arizona • La Jolla, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

NCT03406078
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
21
States / cities
Bakersfield, California • Newark, Delaware • Kissimmee, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT05368285
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Matching Placebo
Biological · Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jul 21, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

NCT05059236
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acoustic Waveform Respiratory Evaluation

NCT06512064
View directory record Official record
Conditions
Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
Interventions
AWARE
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 21, 2026, 4:05 PM EDT
Active, not recruiting Phase 4 Interventional

Investigating Dupilumab's Effect in Asthma by Genotype

NCT03694158
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium

NCT01906528
View directory record Official record
Conditions
Muscle Relaxation, Sex
Interventions
Mivacurium
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Jul 21, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Isocaloric Ultra Processed Versus Unprocessed Diets on Insulin Sensitivity

NCT03189121
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 21, 2026, 4:05 PM EDT
Recruiting No phase listed Observational

A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

NCT07316114
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 21, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels

NCT06934200
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Omalizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

NCT02024204
View directory record Official record
Conditions
Lung Diseases, Medication Compliance
Interventions
Fluticasone propionate 230mcg for 3 Months, Current Treatment or no treatment, Salmeterol 21mcg for 3 Months
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 21, 2026, 4:05 PM EDT
Recruiting No phase listed Observational

Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma

NCT02241265
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cognitive, Emotional, and Neural Responses to Acute Inflammation

NCT03294564
View directory record Official record
Conditions
Healthy
Interventions
Typhoid Vi Polysaccharide Vaccine, Placebo
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Jul 21, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Children's Respiratory and Environmental Workgroup

NCT03213184
View directory record Official record
Conditions
Asthma, Allergic Asthma, Allergies, Healthy
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
10
States / cities
Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 21, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Relationship Between Systemic Fatty Acid Availability and Insulin Sensitivity

NCT01452048
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

Pilot of Lifestyle and Asthma Intervention

NCT03291808
View directory record Official record
Conditions
Asthma
Interventions
Weight loss intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Tucson, Arizona • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise Dose Response for Improving Insulin Sensitivity

NCT01452035
View directory record Official record
Conditions
Obesity
Interventions
Exercise
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

NCT00441376
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Neoplasms
Interventions
ThermoDox
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

NCT03569293
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 4:05 PM EDT
Withdrawn Not applicable Interventional

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

NCT02795143
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Isotretinoin, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Teva Asthma Predictive Analytics Study

NCT04997304
View directory record Official record
Conditions
Asthma
Interventions
AirDuo Digihaler, ProAir Digihaler
Combination Product
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 21, 2026, 4:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis

NCT00227058
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Orotic acid and Glutathione-(Nutritional Supplements)
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Jul 21, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

NCT00435578
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
Glufosfamide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Greenbrae, California • Tampa, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Jul 21, 2026, 4:05 PM EDT
Completed No phase listed Observational

Grass Observational Study

NCT02075138
View directory record Official record
Conditions
Grass Allergy, Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
Circassia Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Normal, Illinois • Sylvania, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Jul 21, 2026, 4:05 PM EDT